SK Biopharm Introduces Epilepsy New Drug Candidate Worth ₩1.1 Trillion… First Trillion-Won Technology Acquisition in Korean Pharmaceutical and Bio Industry

Hyundai Motor's Investor Day announcement failed to meet market expectations, leading to a sharp drop in its stock price. It was pointed out that the company's external communication culture did not align with Korean sentiment, lacking concrete roadmaps or performance presentations that investors desired. In particular, disappointment was high as investors perceive Hyundai Motor as a physical AI company, yet no specific plans such as the IPO of Boston Dynamics were presented.

Cases were mentioned where some pharmaceutical and bio companies caused stock price plunges due to premature information disclosure at external events such as forums. Peptron was cited as a prime example, where content presented at a forum was negatively interpreted by the market, leading to a significant drop in its stock price. This highlights the importance of corporate information disclosure methods and investor communication.

SK Biopharm has secured an epilepsy new drug candidate through a license-in, rather than license-out, model. This is the first technology acquisition deal worth over a trillion won by a Korean bio company, drawing attention with an upfront payment of ₩550 billion that is non-refundable. This agreement is being praised for setting a new milestone in the domestic bio industry.

The U.S. Treasury announced plans to use funds from its Treasury General Account (TGA) to purchase Treasury bonds. This is interpreted as a policy measure aimed at lowering bond yields. Market experts advise not to oppose the U.S. Treasury's policy intentions, predicting that various policy tools to lower bond yields will continuously emerge in the future.

News has emerged that the U.S. administration is preparing to redeploy diplomats to the Middle East. This raises the possibility of an agreement with Iran regarding passage through the Strait of Hormuz, interpreted as a positive signal that the potential for physical conflict in the Middle East may ease. The return of diplomats is seen as part of efforts to improve relations with Iran and stabilize the region.

Despite rumors that the U.S. government requested the Korean government to invest in Westinghouse, and official denials, market expectations persist. This reflects investors' belief in the potential for overseas export of Korean nuclear power plants and the materialization of cooperation with Westinghouse. Although denied, related issues are driving up the stock prices of nuclear power-related companies. This situation indicates increasing domestic and international interest in the nuclear power industry.

Despite denials regarding Westinghouse's IPO and rumors of the Korean government's equity investment, nuclear power stocks continued their strong upward trend. The market, operating under the sentiment of 'no smoke without fire,' continued to buy stocks, holding onto expectations for related issues. This is analyzed as reflecting investors' strong confidence in the government's energy policy direction and the growth of the nuclear power industry. Despite rumors, expectations for the potential of the nuclear power industry are positively influencing the market.

Ahead of Nvidia's earnings announcement, the market is experiencing a mix of anticipation and concern. The pattern of stock prices falling by 2-3% after earnings announcements has repeated for the past four quarters, raising the possibility of a similar trend this time. In particular, Nvidia's guidance expectations have significantly increased from $15 billion to $100 billion, sparking keen interest in whether it can meet these expectations. The revenue outlook for Rubin is also expected to have a significant impact on the stock prices of domestic semiconductor companies such as Samsung Electronics and SK Hynix.

Two key points investors should watch during Nvidia's earnings announcement are the Rubin revenue outlook and the reopening of the Chinese market. How confidently Nvidia will forecast Rubin's shipment volume for next year is crucial, as it could directly impact the performance of domestic semiconductor companies. Additionally, if there are comments regarding the resumption of sales in China, it is expected to have a positive impact on the overall semiconductor market. High interest is focused on Nvidia's announcement, as it could determine the direction of domestic semiconductor companies' stock prices.

Hanmi Pharmaceutical secured technology transfer contracts worth over ₩5 trillion this year, accumulating over ₩9 trillion in remaining technology transfer balances, excluding returned upfront payments. In particular, the GLP-2 analog contract with Eli Lilly and the urocorotin-2 technology transfer contract with Roche's subsidiary Genentech are cited as examples proving Hanmi Pharmaceutical's technological prowess. Based on these achievements, Hanmi Pharmaceutical is emerging as a key leader in the obesity treatment market.

Efpeglenatide, which was previously returned after a ₩5 trillion technology transfer contract with Sanofi, has been repurposed as an obesity treatment and is awaiting domestic launch. It has successfully completed phase 3 clinical trials and is currently awaiting product approval from the Ministry of Food and Drug Safety, with a launch expected as early as October this year. This will be a significant turning point for Hanmi Pharmaceutical, overcoming past setbacks and pioneering a new obesity treatment market.

It has been argued that Hanmi Pharmaceutical's current market capitalization of ₩6.7 trillion is undervalued, even after securing ₩380 billion in upfront payments through technology transfer contracts with Eli Lilly and Roche. Comparing it to the past case where ABL Bio's market capitalization exceeded ₩10 trillion, it is pointed out that Hanmi Pharmaceutical, despite being a leading obesity treatment stock, is not receiving sufficient market recognition for its value. This analysis is based on the belief that the current stock price is excessively low compared to Hanmi Pharmaceutical's technological prowess and future growth potential.

SK Biopharm has signed a ₩1.1 trillion technology acquisition deal with U.S. Biohaven for two opacalim epilepsy drug candidates. This contract, with an upfront payment of ₩550 billion, is set to be recorded as an unprecedented large-scale technology acquisition in the history of the Korean pharmaceutical and bio industry. Through this agreement, SK Biopharm aims to proactively secure competitive new drug candidates and strengthen its dominance in the epilepsy treatment market. This bold investment is expected to positively impact the overall domestic bio industry.

SK Biopharm has made an unprecedented large-scale investment in the domestic bio industry by signing a technology acquisition deal worth over a trillion won. This case demonstrates that the time has come for Korean bio companies to make bold investments to secure competitiveness in the global market. This agreement is expected to positively impact SK Biopharm's Xcopri sales outlook and serve as a crucial variable in the change of supply and demand trends for domestic pharmaceutical and bio companies.

News has emerged that newly listed Ingenia Therapeutics is in the process of a technology transfer contract with U.S. Merck (MSD). This is a significant factor that enhances Ingenia Therapeutics' future growth potential, with even the possibility of reaching a market capitalization of ₩1 trillion being mentioned. As a newly listed stock, it is attracting significant market attention, and stock price volatility is expected to increase depending on the specific details of the technology transfer contract.

Tonight, the announcement of important economic data, the Personal Consumption Expenditures (PCE) index, is scheduled, and tomorrow morning, Nvidia's earnings announcement is emerging as the market's biggest concern. The PCE index is important as it can influence the U.S. Federal Reserve's interest rate policy, and Nvidia's earnings are a key indicator for gauging the direction of the overall semiconductor industry. Investors should monitor these two major events and prepare for market volatility.